In a report released today, Caroline Palomeque from Maxim Group maintained a Buy rating on Soleno Therapeutics Inc (NASDAQ: SLNO), with a price target of $4. The company’s shares opened today at $1.87.
Palomeque observed:
“Soleno announced that it will present two poster presentations on 57 th Athens, Greece. The late-breaking posters will show PK and clinical data as well as the glycemic impact of diazoxide chloride controlled release (DCCR) use, long- term, in Prader-Willi Syndrome (PWS). Conclusion: We view the posters as an opportunity to showcase the potential benefit of DCCR in PWS in the EU. Focus remains on the Phase 3 trial of DCCR in PWS which is enrolling, data in 1H19.”
According to TipRanks.com, Palomeque has 0 stars on 0-5 star ranking scale with an average return of -5.8% and a 34.5% success rate. Palomeque covers the Healthcare sector, focusing on stocks such as VistaGen Therapeutics, Anavex Life Sciences, and Daré Bioscience Inc.
The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Soleno Therapeutics Inc with a $9 average price target.
See today’s analyst top recommended stocks >>
The company has a one-year high of $3.63 and a one-year low of $1.32. Currently, Soleno Therapeutics Inc has an average volume of 214.9K.
Based on the recent corporate insider activity of 32 insiders, corporate insider sentiment is negative on the stock.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Soleno Therapeutics, Inc. is a healthcare company, focused on the development and commercialization of novel therapeutics for the treatment of rare diseases. It markets CoSense End-Tidal Carbon Monoxide monitor, which measures ETCO and is used by hospitals to detect hemolysis in newborns.
